Group One Trading
AVDL

Group One Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Group One Trading’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,900
Closed -$256K – 7628
2025
Q4 		$256K Sell
11,900
-84,100
-88% -$1.63M ﹤0.01% 4143
2025
Q3 		$1.47M Buy
96,000
+79,600
+485% +$1.04M ﹤0.01% 2632
2025
Q2 		$145K Sell
16,400
-17,500
-52% -$154K ﹤0.01% 4649
2025
Q1 		$265K Sell
33,900
-166,200
-83% -$1.39M ﹤0.01% 3730
2024
Q4 		$2.1M Sell
200,100
-247,600
-55% -$3.01M ﹤0.01% 1865
2024
Q3 		$5.87M Buy
447,700
+430,300
+2,473% +$6.55M 0.02% 910
2024
Q2 		$245K Sell
17,400
-169,200
-91% -$2.76M ﹤0.01% 3228
2024
Q1 		$3.15M Buy
186,600
+150,600
+418% +$2.24M 0.01% 1156
2023
Q4 		$508K Buy
36,000
+13,300
+59% +$156K ﹤0.01% 3054
2023
Q3 		$234K Sell
22,700
-266,700
-92% -$3.57M ﹤0.01% 3667
2023
Q2 		$4.77M Buy
289,400
+254,200
+722% +$3.3M 0.02% 985
2023
Q1 		$322K Sell
35,200
-17,400
-33% -$143K ﹤0.01% 3195
2022
Q4 		$377K Buy
52,600
+20,100
+62% +$141K ﹤0.01% 3306
2022
Q3 		$163K Sell
32,500
-7,400
-19% -$40.7K ﹤0.01% 4334
2022
Q2 		$97K Buy
39,900
+7,700
+24% +$31.6K ﹤0.01% 5012
2022
Q1 		$220K Buy
32,200
+19,800
+160% +$136K ﹤0.01% 4698
2021
Q4 		$100K Buy
12,400
+11,000
+786% +$101K ﹤0.01% 5720
2021
Q3 		$14K Sell
1,400
-5,700
-80% -$44.9K ﹤0.01% 7336
2021
Q2 		$48K Sell
7,100
-29,000
-80% -$230K ﹤0.01% 6608
2021
Q1 		$326K Buy
36,100
+14,700
+69% +$119K ﹤0.01% 4502
2020
Q4 		$143K Buy
21,400
+2,600
+14% +$16.3K ﹤0.01% 4309
2020
Q3 		$95K Sell
18,800
-4,000
-18% -$29.1K ﹤0.01% 4223
2020
Q2 		$184K Sell
22,800
-20,200
-47% -$178K ﹤0.01% 3447
2020
Q1 		$341K Buy
43,000
+12,000
+39% +$92.2K ﹤0.01% 2332
2019
Q4 		$234K Buy
+31,000
New +$164K ﹤0.01% 3058
2019
Q1 		– Sell
-8,700
Closed -$22K – 4782
2018
Q4 		$22K Sell
8,700
-10,400
-54% -$35.4K ﹤0.01% 3986
2018
Q3 		$84K Buy
19,100
+12,400
+185% +$67K ﹤0.01% 3642
2018
Q2 		$41K Sell
6,700
-29,400
-81% -$206K ﹤0.01% 4051
2018
Q1 		$263K Buy
36,100
+30,800
+581% +$271K ﹤0.01% 2574
2017
Q4 		$43K Buy
5,300
+4,800
+960% +$45K ﹤0.01% 3809
2017
Q3 		$5K Buy
+500
New +$4.77K ﹤0.01% 4469
2017
Q1 		– Sell
-8,300
Closed -$86K – 4611
2016
Q4 		$86K Sell
8,300
-23,400
-74% -$257K ﹤0.01% 2922
2016
Q3 		$393K Buy
31,700
+2,000
+7% +$26.1K ﹤0.01% 1993
2016
Q2 		$319K Buy
+29,700
New +$317K ﹤0.01% 2066
2016
Q1 		– Sell
-1,000
Closed -$12K – 4546
2015
Q4 		$12K Sell
1,000
-14,000
-93% -$218K ﹤0.01% 4104
2015
Q3 		$245K Buy
15,000
+800
+6% +$17.6K ﹤0.01% 2358
2015
Q2 		$301K Sell
14,200
-31,800
-69% -$570K ﹤0.01% 2223
2015
Q1 		$827K Sell
46,000
-1,000
-2% -$15.7K 0.01% 1229
2014
Q4 		$805K Buy
47,000
+35,800
+320% +$511K 0.01% 1200
2014
Q3 		$160K Buy
11,200
+8,400
+300% +$121K ﹤0.01% 2561
2014
Q2 		$42K Buy
2,800
+2,100
+300% +$25.3K ﹤0.01% 3656
2014
Q1 		$9K Buy
+700
New +$7.5K ﹤0.01% 4619
2013
Q3 		– Sell
-600
Closed -$4K – 5197
2013
Q2 		$4K Buy
+600
New +$3.1K ﹤0.01% 4736

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Group One Trading's AVDL Position: Q1 2026 in Review

Group One Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 93,028 shares — an estimated $2M sold.

Group One Trading first reported a position in AVDL in Q2 2013 and held it in 34 quarters. The position peaked at $2M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • Group One Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Group One Trading sold 93,028 Avadel Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Group One Trading first reported a position in Avadel Pharmaceuticals in Q2 2013 and held it in 34 quarters.
  • Group One Trading's Avadel Pharmaceuticals position peaked at $2M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.